Lv1
5 积分 2020-08-25 加入
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial
5个月前
已完结
CSF Concentration of Crizotinib in Two ALK-Positive Non–Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment
7个月前
已完结
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
7个月前
已完结
P3.08F.01 Interim Analysis of a Phase 2 Prospective Trial of Induction Lorlatinib in Locally Advanced ALK-Positive NSCLC (LORIN)
7个月前
已关闭
The mechanisms of resistance to second- and third-generation ALK inhibitors and strategies to overcome such resistance
8个月前
已完结
Comparative Efficacy and Safety of Lorlatinib vs. Alectinib and Lorlatinib vs. Brigatinib for ALK-positive Advanced/Metastatic NSCLC: Matching-Adjusted Indirect Comparisons
8个月前
已完结
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
8个月前
已完结
Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer
8个月前
已关闭
The International Association for the Study of Lung Cancer Staging Project for Lung Cancer: Proposals for the Revision of the M Descriptors in the Forthcoming Ninth Edition of the TNM Classification for Lung Cancer
10个月前
已完结
Randomized Trial of Surgery Versus Radiotherapy in Patients with Stage IIIA (N2) Non–Small-Cell Lung Cancer After a Response to Induction Chemotherapy: EORTC 08941
10个月前
已完结
皖公网安备34019202002308
